TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial Academic Article uri icon

Overview

MeSH Major

  • Fibrinolytic Agents
  • Myocardial Infarction
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator

abstract

  • TNK-tPA, given as a single 40-mg bolus, achieved rates of TIMI grade 3 flow similar to those of the 90-minute bolus and infusion of tPA. Weight-adjusting TNK-tPA appears to be important in achieving optimal reperfusion; reduced heparin dosing appears to improve safety for both agents. Together with the safety results from the parallel Assessment of the Safety of a New Thrombolytic: TNK-tPA (ASSENT I) trial, an appropriate dose of this single-bolus thrombolytic agent has been identified for phase III testing.

publication date

  • December 22, 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9860780

Additional Document Info

start page

  • 2805

end page

  • 14

volume

  • 98

number

  • 25